Publicaciones (20) Publicaciones de MARÍA GARCÍA-CREMADES MIRA

2024

  1. Computer simulations in pharmacokinetics

    Physico-Chemical Aspects of Dosage Forms and Biopharmaceutics: Recent and Future Trends in Pharmaceutics, Volume 2 (Elsevier), pp. 353-366

  2. Pharmacokinetic-pharmacodynamic modeling of tuberculosis time to positivity and colony-forming unit to assess the response to dose-ranging linezolid

    Antimicrobial agents and chemotherapy, Vol. 68, Núm. 8, pp. e0019024

2023

  1. Editorial: Innovative pharmacometric approaches to inform drug development and clinical use

    Frontiers in Pharmacology

2022

  1. Characterizing HIV-Preventive, Plasma Tenofovir Concentrations—A Pooled Participant-level Data Analysis From Human Immunodeficiency Virus Preexposure Prophylaxis Clinical Trials

    Clinical Infectious Diseases, Vol. 75, Núm. 11, pp. 1873-1882

  2. Combination of Mycobacterium tuberculosis RS Ratio and CFU Improves the Ability of Murine Efficacy Experiments to Distinguish between Drug Treatments

    Antimicrobial Agents and Chemotherapy, Vol. 66, Núm. 4

  3. Emerging Therapeutics, Technologies, and Drug Development Strategies to Address Patient Nonadherence and Improve Tuberculosis Treatment

    Annual review of pharmacology and toxicology, Vol. 62, pp. 197-210

  4. Modeling the Probability of HIV Infection over Time in High-Risk Seronegative Participants Receiving Placebo in Five Randomized Double-Blind Placebo-Controlled HIV Pre-Exposure Prophylaxis Trials: A Patient-Level Pooled Analysis

    Pharmaceutics, Vol. 14, Núm. 9

  5. Population Pharmacokinetic/Pharmacodynamic Modelling of Daptomycin for Schedule Optimization in Patients with Renal Impairment

    Pharmaceutics, Vol. 14, Núm. 10

2021

  1. A Mechanistic In Vivo/Ex Vivo Pharmacokinetic-Pharmacodynamic Model of Tenofovir for HIV Prevention

    CPT: Pharmacometrics and Systems Pharmacology, Vol. 10, Núm. 3, pp. 179-187

  2. Clinical Pharmacokinetics of Oral Sodium Selenite and Dosing Implications in the Treatment of Patients with Metastatic Cancer

    Drugs in R and D, Vol. 21, Núm. 2, pp. 169-178

  3. Mycobacterium tuberculosis precursor rRNA as a measure of treatment-shortening activity of drugs and regimens

    Nature Communications, Vol. 12, Núm. 1

  4. Oxypurinol pharmacokinetics and pharmacodynamics in healthy volunteers: Influence of BCRP Q141K polymorphism and patient characteristics

    Clinical and Translational Science, Vol. 14, Núm. 4, pp. 1431-1443

2020

  1. Mechanistic Multiscale Pharmacokinetic Model for the Anticancer Drug 2’,2’-difluorodeoxycytidine (Gemcitabine) in Pancreatic Cancer

    Clinical and Translational Science, Vol. 13, Núm. 3, pp. 608-617

  2. Optimizing Hydroxychloroquine Dosing for Patients With COVID-19: An Integrative Modeling Approach for Effective Drug Repurposing

    Clinical Pharmacology and Therapeutics, Vol. 108, Núm. 2, pp. 253-263

  3. Response to “Quantitative Clinical Pharmacology INPUT to SARS-CoV-2 Therapeutics Should be Based on Robust Data”

    Clinical Pharmacology and Therapeutics

2019

  1. Pharmacokinetics, optimal dosing, and safety of linezolid in children with multidrug-resistant tuberculosis: Combined data from two prospective observational studies

    PLoS Medicine, Vol. 16, Núm. 4

  2. Translational Framework Predicting Tumour Response in Gemcitabine-Treated Patients with Advanced Pancreatic and Ovarian Cancer from Xenograft Studies

    AAPS Journal, Vol. 21, Núm. 2

2018

  1. Predicting tumour growth and its impact on survival in gemcitabine-treated patients with advanced pancreatic cancer

    European Journal of Pharmaceutical Sciences, Vol. 115, pp. 296-303

  2. Systematic modeling and design evaluation of unperturbed tumor dynamics in xenografts

    Journal of Pharmacology and Experimental Therapeutics, Vol. 366, Núm. 1, pp. 96-104

2017

  1. Characterizing gemcitabine effects administered as single agent or combined with carboplatin in mice pancreatic and ovarian cancer xenografts: A semimechanistic pharmacokinetic/pharmacodynamics tumor growth-response model

    Journal of Pharmacology and Experimental Therapeutics, Vol. 360, Núm. 3, pp. 445-456